Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

PRIMARY OBJECTIVES: * To assess the safety of chemotherapy isolated to the pulmonary circulation by determining the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of each chemotherapy agent. (Phase I) * To determine the rate of local recurrences in patients receiving pulmonary suffusion, compared to historical controls in patients with completely resected pulmonary metastases (unilateral and bilateral disease). (Phase II) * To support the safety of chemotherapy isolated to the pulmonary circulation by evaluating adverse events at an oxaliplatin dose of 12.75 mg/m2 (15% systemic), as established by completion of Phase I in this trial. SECONDARY OBJECTIVES: * To determine the local and systemic toxicities associated with pulmonary suffusion. (Phase I) * To determine whether suffusion improves metastatic control by suppressing progression of microscopic metastases to new lesions assessable by imaging (Phase I) * To determine disease-free survival (DFS) in patients receiving pulmonary suffusion compared to historical controls, in patients with completely resected pulmonary metastases (unilateral and bilateral disease). (Phase II) * To continue to refine the surgical and interventional techniques of suffusion within the framework established by the clinical trial (Phase II) EXPLORATORY OBJECTIVES: I. To evaluate the pulmonary suffusion-associated changes in local tumor microenvironment (TME) and potential of suffusion as an immune modulation enhancement. (Phase II) II. To determine overall survival (OS) in patients receiving pulmonary suffusion compared to historical controls, in patients with completely resected pulmonary metastases (unilateral and bilateral disease). (Phase II) III. To compare histology of tumor samples with previously resected specimens with attention to biomarkers of systemic immune recognition in patients eligible for repeat suffusion. (Phase II) IV. To obtain tumor and systemic immune biomarkers including cytokine activations for correlation with clinical responses. (Phase II) V. To correlate local control with biomarker for tissue effect from chemotherapy (including tissue levels of platinum, alkaline phosphatase \[ALP\]). (Phase II) VI. To correlate local disease control with tumor biomarker for metastasis (circulating \[circ\] ribonucleic acid \[RNA\], micro \[mi\]RNA). (Phase II) OUTLINE: Patients undergo pulmonary suffusion consisting of cisplatin via infusion. Patients then undergo metastasectomy. Patients found to have unresectable sarcoma may receive chemotherapy within 4-8 weeks of metastasectomy. After completion of study treatment, patients are followed up for 3 months for one year and then every 6 months for up to 5 years.